Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01520220
First received: January 10, 2012
Last updated: April 4, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)